UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Dec

13 Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Read More Share:

Dec

09 UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Read More Share:

Dec

07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Nov

17 Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:

Nov

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Nov

10 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:

Nov

08 UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Read More Share:

Oct

12 Advancing Science to Better Care for Epilepsy Patients

Read More Share:

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Oct

12

Advancing Science to Better Care for Epilepsy Patients

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Dec

13

Employee Spotlight: Leah VanderVeen and Her Time as a Court Appointed Special Advocate for Foster Children

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Oct

12

Advancing Science to Better Care for Epilepsy Patients

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact